BTIG Reiterates Buy on Spyre Therapeutics, Maintains $70 Price Target

BTIG analyst Julian Harrison has reiterated a Buy rating on Spyre Therapeutics (NASDAQ: SYRE) and maintained a price target of $70 for the stock. This endorsement suggests confidence in the company's future performance.